iCo Therapeutics Inc. News Releases http://www.icotherapeutics.com/investor_relations/news_releases/ iCo Therapeutics Inc. News Releases Mon, 01 Sep 2014 16:20:14 en <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Second Quarter 2014 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=214 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Positive Oral Amphotericin B Study Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=213 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=212 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=211 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces First Quarter 2014 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=209 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Poster Presentation at ARVO</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=207 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Year End 2013 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=206 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=205 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces DTC Approval</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=204 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=199 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=198 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=197 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Begins Trading on the OTCQX Marketplace</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=196 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=194 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics To Present At Jefferies Ophthalmic Therapeutic Summit</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=193 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Third Quarter 2013 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=192 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at the 6th Annual LD MICRO</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=191 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Warrant Exercise</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=190 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at the Ophthalmology Innovation Summit</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=188 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Grants Options to a Director</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=187 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=186 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Second Quarter 2013 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=189 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=184 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces First Quarter 2013 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=183 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=182 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Closes $3.4 Million Financing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=181 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=185 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Raise $3.2 Million</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=180 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Overnight Marketed Equity Offering</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=179 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Year End 2012 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=178 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=177 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=176 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Grants Options to Directors, Officers and Employees</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=175 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=172 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Third Quarter 2012 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=170 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics' Oral Amphotericin B Delivery System to be Presented at AAPS with Updated Patent Position</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=167 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=162 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Second Quarter 2012 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=161 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Closes $2.55 Million Financing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=160 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Raise $2.55 Million</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=159 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Overnight Marketed Equity Offering</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=158 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=156 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces First Quarter 2012 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=157 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Year End 2011 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=154 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=152 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics CEO to Present at Retinal Physician Symposium 2012</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=151 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Appoints Douglas Janzen to Board of Directors</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=148 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Retains Crescendo Communications</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=145 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Execution of Equity Line Facility Agreement</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=143 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Third Quarter 2011 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=142 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Closes $1,115,000 Non-Brokered Private Placement</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=141 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Oral Amphotericin B Delivery System to be Presented at AAPS</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=140 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics CEO to Present at the Ophthalmology Innovation Summit</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=139 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Grants Options to Directors, Officers and Employees</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=138 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=137 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics CEO to Present & Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=136 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Second Quarter 2011 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=135 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Key iCo-007 Clinical Development Milestone</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=134 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Resignation of John Clement, Chief Technology and Development Officer and Director</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=133 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Engages The Equicom Group</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=132 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics CMO to Present at The Drug Repositioning Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=131 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces First Quarter 2011 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=130 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=125 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics CEO to Present & Participate in Panel at BioFinance 2011</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=124 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=122 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Year-End 2010 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=121 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Secures $10 Million Equity Line Facility</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=120 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. iCo-007 Program to be Presented &amp; CEO to Sit on Panel at Retinal Physician Symposium 2011</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=119 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=118 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Extends Investor Relations Engagement with The Trout Group</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=115 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=114 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Reports Third Quarter 2010 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=113 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Selected as Canada's Top 10TM Competition Winner</span> TM Competition winners. Top 10TM winners are chosen by an inde...]]> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=108 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=107 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=105 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Second Quarter 2010 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=100 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. receives Health Canada Clearance to Conduct Phase II DME Trial with iCo-007</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=97 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. enters into Investor Relations Engagements with The Trout Group and Sector Speak</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=98 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces First Quarter 2010 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=96 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. enters into Technology Transfer Agreement with Isis Pharmaceuticals, Inc. for iCo-007</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=94 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics iCo-007 Phase I Clinical Trial Meets Primary Endpoint</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=93 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces Year-End 2009 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=90 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. engages Susan Koppy to spearhead iCo-007 out-licensing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=89 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo-007 for Diffuse Diabetic Macular Edema to be Presented at Retinal Physician Symposium 2010</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=82 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. Recognized by BIOTECanada with Gold Leaf Award</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=92 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics iCo-007 Overview to be Presented at the 8th International Symposium on Ocular Pharmacology and Therapeutics</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=103 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Q3 2009 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=110 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Q2 2009 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=111 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Appoints Infectious Disease MD to Scientific Advisory Board</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=101 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Closes Non-Brokered Private Placement</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=95 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Diabetic Macular Edema Clinical Trial Update</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=102 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Oral Amphotericin B Poster at AAPS</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=58 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Third Quarter Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=104 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=59 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=60 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Selected as Canada's Top 10TM Competition Winner</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=61 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at BioContact Québec</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=62 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Provides Interim Trial Results (Diffuse Diabetic Macular Edema)</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=63 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Outlines Steps to First iCo-009 Human Clinical Trial</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=64 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Second Quarter Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=65 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Appoints Mr. Noel Hall and Dr. Christian Fibiger to Board</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=66 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=67 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Closes $1,140,450 Financing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=68 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces $1,140,450 Financing</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=69 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics First Quarter Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=70 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Acquires Worldwide Rights to iCo-009 (Oral Amphotericin B)</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=71 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics to Present at BioFinance 2008</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=72 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Year-End 2007 Financial Results</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=73 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics iCo-007 Diabetic Macular Edema Poster Presentation at ARVO</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=74 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces iCo-009 (Oral Amphotericin B) FDA Meeting</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=75 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=106 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Provides iCo-008 Phase II Clinical Update</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=77 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Announces CMO Invited to Present at International Ocular Conference</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=78 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Update</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=79 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Inc. and Beanstalk Capital Ltd. Announce Completion of Arrangement</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=80 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=81 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc.</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=83 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=84 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=85 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">iCo Therapeutics announces licensing deal</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=86 D, d M Y H:i:s <span style="font:Tahoma, Helvetica, sans-serif">Cambridge Antibody Tech. licenses monoclonal antibody for treatment of allergy disorders to iCo</span> http://www.icotherapeutics.com/investor_relations/news_releases/index.php?&content_id=87 D, d M Y H:i:s